Approximately 1 in 3 patients with RA who discontinued tofacitinib maintained low disease activity after 1 year.
This article discusses the most prevalent risk factors, as well as the clinical signs and symptoms, associated with RA.
"Within patients with clinically suspect arthralgia, anti-citrullinated protein antibody was associated with increased risks on progression to clinical arthritis."
Clinical Pain Advisor Articles
- Supervised Injection Sites: Facts, Information, Pros, and Cons
- Chronic Pain May Be a Contributing Factor to Suicide
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Reviewing the Efficacy of Invasive Procedures for Chronic Back, Knee Pain
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Lower Weighting of Hand Cortical Representations in CRPS
- Predicting Success of Focal Nerve Surgery Based on Diagnostic Block Response
- Aetna-CVS Merger Approved
- FDA Announces Draft Guidance for Consumer OTC Access to Previously Prescription Drugs
- Maryland Legislature: Will Federal Courts Permit State Regulation of Drug Prices?